In summary, depending on the tumor type, PTPN13 may regulate resistance to anti-cancer therapies through its anti-apoptotic role via the FAS pathway, or through regulation of secondary EGFR pathways (ephrinB1/ErbB and SRC/PKD1/AKT), or through an indirect action on microtubules mediated by ephrinB1. Here, SRC is linked to cancer.